Interferon α 2b Pharmacovigilance Study
Primary Purpose
Hepatitis C, Chronic
Status
Completed
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
interferon α 2b + ribavirin
Sponsored by
About this trial
This is an interventional treatment trial for Hepatitis C, Chronic focused on measuring Hepatitis C, Chronic, Genotype 2/3, Interferon α 2b, Ribavirin, Pharmacovigilance
Eligibility Criteria
Inclusion Criteria:
- Genotype 2/3 Chronic Hepatitis C confirmed by biomolecular technology (RNAVHC);
- Treatment naive;
- Signing the Informed Consent Form;
- Eligibility criteria and outcome measures followed the Clinical Protocol and Therapeutic Guidelines for Chronic Viral Hepatitis C, published by the Ministry of Health: http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf
Exclusion Criteria:
- Serious adverse events;
- Intolerance to treatment;
- Lost to follow up.
Sites / Locations
- Hospital Universitário Clementino Fraga Filho (Clementino Fraga Filho University Hospital)
- Hospital Federal de Bonsucesso (Bonsucesso Federal Hospital)
Outcomes
Primary Outcome Measures
Adverse events
Diary for recording adverse events by patients daily;
Monthly follow-up interview with MD and PharmD
Secondary Outcome Measures
Sustained virological response
Full Information
NCT ID
NCT01841775
First Posted
April 19, 2013
Last Updated
April 24, 2013
Sponsor
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Collaborators
Hospital Federal de Bonsucesso (Bonsucesso Federal Hospital), Hospital Universitário Clementino Fraga Filho
1. Study Identification
Unique Protocol Identification Number
NCT01841775
Brief Title
Interferon α 2b Pharmacovigilance Study
Official Title
Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da Alfainterferona 2b Humana Recombinante Produzida Por Bio-Manguinhos - Fiocruz, Utilizada em Portadores de Hepatite C crônica genótipos 2 e 3 Atendidos Pelo Programa de Medicamentos de Dispensação em Caráter Excepcional no Estado do Rio de Janeiro)
Study Type
Interventional
2. Study Status
Record Verification Date
April 2013
Overall Recruitment Status
Completed
Study Start Date
May 2009 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
December 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Collaborators
Hospital Federal de Bonsucesso (Bonsucesso Federal Hospital), Hospital Universitário Clementino Fraga Filho
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Multicenter prospective follow-up of a not controlled chronic hepatitis C genotypes 2/3 patients cohort with treatment indication with interferon α 2b and ribavirin for 24 weeks, and the verification of sustained virological response at week 48.
The eligibility criteria and outcome measures followed the Clinical Protocol and Therapeutic Guidelines for Chronic Viral Hepatitis C, published by the Ministry of Health:
http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis C, Chronic
Keywords
Hepatitis C, Chronic, Genotype 2/3, Interferon α 2b, Ribavirin, Pharmacovigilance
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
85 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
interferon α 2b + ribavirin
Intervention Description
interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks
ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks
Primary Outcome Measure Information:
Title
Adverse events
Description
Diary for recording adverse events by patients daily;
Monthly follow-up interview with MD and PharmD
Time Frame
Up to 24 weeks
Secondary Outcome Measure Information:
Title
Sustained virological response
Time Frame
24 weeks after finishing treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Genotype 2/3 Chronic Hepatitis C confirmed by biomolecular technology (RNAVHC);
Treatment naive;
Signing the Informed Consent Form;
Eligibility criteria and outcome measures followed the Clinical Protocol and Therapeutic Guidelines for Chronic Viral Hepatitis C, published by the Ministry of Health: http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf
Exclusion Criteria:
Serious adverse events;
Intolerance to treatment;
Lost to follow up.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eliane M. dos Santos, MD, MSc
Organizational Affiliation
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Paulo Roberto G. dos Santos, PharmD, MSc
Organizational Affiliation
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Deborah A. da Conceição, BScN
Organizational Affiliation
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Official's Role
Study Director
Facility Information:
Facility Name
Hospital Universitário Clementino Fraga Filho (Clementino Fraga Filho University Hospital)
City
Rio de Janeiro
State/Province
RJ
ZIP/Postal Code
21941-913
Country
Brazil
Facility Name
Hospital Federal de Bonsucesso (Bonsucesso Federal Hospital)
City
Rio de Janeiro
ZIP/Postal Code
21041-030
Country
Brazil
12. IPD Sharing Statement
Links:
URL
http://www.bio.fiocruz.br
Description
Related Info
Learn more about this trial
Interferon α 2b Pharmacovigilance Study
We'll reach out to this number within 24 hrs